Amylyx Pharmaceuticals announces the price of an initial public offering plus common shares

CAMBRIDGE, Mass., January 7, 2022– (COMMERCIAL THREAD) – Amylyx Pharmaceuticals, Inc. (“Amylyx”), a clinical-stage pharmaceutical company working to develop a novel treatment for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, today announced the award of its initial public offering plus 10,000,000 common shares in accordance with registration statements on Form S-1 filed with the United States Securities and Exchange Commission (“SEC”) at an initial public offering price of 19 . $ 00 per share.

All common shares are offered by Amylyx. Amylyx has granted the underwriters a 30 day option to purchase up to 1,500,000 additional common shares at the initial public offering price, less subscription discounts and commissions. The gross proceeds of this offering for Amylyx are expected to be $ 190 million, before the deduction of underwriting discounts and commissions, and offering costs, and the exercise of the underwriters’ option to purchase additional shares.

Amylyx common shares are expected to begin trading on the Nasdaq Global Select Market under the symbol “AMLX” on January 7, 2022. The offer is expected to close on or around January 11, 2022, subject to the satisfaction of the conditions of usual closing. .

Goldman Sachs & Co. LLC, SVB Leerink and Evercore ISI are acting as co-book managers for the offering. HC Wainwright & Co. acts as the leader of the offering.

The registration statements on Form S-1 relating to these securities were declared effective by the SEC on January 6, 2022. The offering is being made only by way of prospectus. Copies of the final prospectus relating to the offering may be obtained, when available, from: Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, New York 10282, by telephone at 1- 866-471- 2526 or by e-mail at [email protected]; SVB Leerink LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by phone at 1-800-808-7525, ext. 6105, or by email at [email protected]; or Evercore Group LLC, Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, by phone at 1-888-474-0200, or by email at [email protected] .

This press release does not constitute an offer to sell or the solicitation of an offer to buy any such securities, and there will be no sale of such securities in any state or jurisdiction where such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company working to develop a new treatment for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.

Forward-looking statements
Statements in this press release regarding matters that are not historical facts are “forward-looking statements”, including with respect to the Offer. No guarantee can be given that the offer discussed above will be made. Since these statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. All forward-looking statements contained in this statement are based on management’s current expectations regarding future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those stated. or implied by these forward-looking statements. . Risks that contribute to the uncertain nature of forward-looking statements include the risks and uncertainties set forth in Amylyx’s registration statements on Form S-1 filed with the United States Securities and Exchange Commission and the preliminary prospectus therein. is included. Copies of the registration statements can be viewed by visiting the Securities and Exchange Commission website at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Amylyx assumes no obligation to update these statements to reflect events that occur or circumstances that exist after the date on which they were made.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220106005955/en/

Contacts

Media
Becky gohsler
Finnish partners
(646) 307-6307
[email protected]

Investors
Jacques Frates
Amylyx Pharmaceutical
(857) 320-6230
[email protected]

About Barbara J. Ross

Check Also

National Western Stock Show traditions will continue despite COVID – CBS Denver

DENVER (CBS4) – The National Western Stock Show opens this weekend, despite the increase in …